Health

Results: 7417-7428 of 8082

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

PR Newswire associated0

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

PR Newswire associated0

Millar to Acquire Sentron; Redefining MEMS Pressure Sensor Industry

Business Wire logo

Sofinnova Partners Enhances Leadership in Medtech Acceleration with Key Appointments

PR Newswire associated0

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

Business Wire logo

Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

PR Newswire associated0

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

Business Wire logo

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

PR Newswire associated0

FibroScan® by Echosens Recognized in AASLD Practice Guidance on Managing Portal Hypertension and Varices in Cirrhosis

NuCana Announces Listing Transfer to Nasdaq Capital Market

FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting

PR Newswire associated0

Seegene Earns Improved ESG Rating from the Korea Institute of Corporate Governance and Sustainability